ORIAce-001 is under clinical development by Sanofi and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ORIAce-001’s likelihood of approval (LoA) and phase transition for Acne Vulgaris took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ORIAce-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ORIAce-001 overview

ORIAce-001 is under development for the prevention and treatment of acne vulgaris caused by Propionibacterium acnes and to prevent implant-associated Propionibacterium acnes infections. It is based on protection based vaccine discovery (ProVaDis) technology. It is administered through intramuscular and intradermal route.

Sanofi overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Quick View ORIAce-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • ORIAce-001
Administration Pathway
  • Intradermal
  • Intramuscular
Therapeutic Areas
  • Dermatology
Key Developers
  • Sponsor Company: Sanofi
  • Originator: Origimm Biotechnology
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.